AISLING CAPITAL III LP's Net Worth
$281 Million
Who is AISLING CAPITAL III LP?
AISLING CAPITAL III LP has an estimated net worth of $281 Million. This is based on reported shares across multiple companies, which include Zeltiq Aesthetics Inc, Loxo Oncology, Inc., AGILE THERAPEUTICS INC, Syros Pharmaceuticals, Inc., T2 Biosystems, Inc., SafeStitch Medical, Inc., Durata Therapeutics, Inc., and Versartis, Inc..
SEC CIK
AISLING CAPITAL III LP's CIK is 0001444717
Past Insider Trading and Trends
2015 was AISLING CAPITAL III LP's most active year for acquiring shares with 4 total transactions. AISLING CAPITAL III LP's most active month to acquire stocks was the month of October. 2014 was AISLING CAPITAL III LP's most active year for disposing of shares, totalling 4 transactions. AISLING CAPITAL III LP's most active month to dispose stocks was the month of April. 2015 saw AISLING CAPITAL III LP paying a total of $9,203,022.78 for 343,869 shares, this is the most they've acquired in one year. In 2018 AISLING CAPITAL III LP cashed out on 1,400,000 shares for a total of $251,202,000.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Zeltiq Aesthetics Inc No price found
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -27.55% | -990.77K |
—
|
—
| 2.61M |
Jan 23
| |||
Form 4
| -13.78% | -575.00K |
$12.22 | -$7,026,500.00 | 3.6M |
Nov 14
| |||
Form 4
| +22.60% | 769.23K |
$13.00 | $10,000,003.00 | 4.17M |
Oct 24
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Loxo Oncology, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -40.71% | -1.40M |
$179.43 | -$251,202,000.00 | 2.04M |
Jul 10
| |||
Form 4
| -6.78% | -250.00K |
$80.50 | -$20,125,000.00 | 3.44M |
Dec 19
| |||
Form 4
| -11.94% | -500.00K |
$75.00 | -$37,500,000.00 | 3.69M |
Nov 22
| |||
Form 4
| +3.97% | 160K |
$31.00 | $4,960,000.00 | 4.19M |
Jan 10
| |||
Form 4
| +6.13% | 232.56K |
$21.50 | $4,999,997.00 | 4.03M |
May 17
| |||
Form 4
| +0.01% | 200 |
$27.50 | $5,500.00 | 3.8M |
Dec 11
| |||
Form 4
| +7.50% | 265K |
$26.50 | $7,022,500.00 | 3.8M |
Nov 17
| |||
Form 4
| +1.13% | 78.67K |
$27.56 | $2,175,022.78 | 7.06M |
Nov 12 - Nov 13
| |||
Form 4
| +1,729.55% | 3.26M |
$13.00 | $5,370,001.00 | 3.45M |
Aug 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AGILE THERAPEUTICS INC (AGRX) Snapshot price: $1.49
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -13.41% | -400.00K |
—
|
—
| 2.58M |
Jun 2
| |||
Form 4
| +37.39% | 811.97K |
$5.85 | $4,750,001.10 | 2.98M |
Jan 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Syros Pharmaceuticals, Inc. (SYRS) Snapshot price: $1.6
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 908.57K |
$12.50 |
—
| 908.57K |
Jul 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
T2 Biosystems, Inc. (TTOO) Snapshot price: $2.94
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +12.19% | 307.69K |
$9.75 | $2,999,997.00 | 2.83M |
Dec 9
| |||
Form 4
|
∞
| 2.52M |
$11.00 | $4,999,995.00 | 2.52M |
Aug 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||